Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Sulfonamide allergy in HIV-uninfected patients

Anthony Montanaro, MD, FAAAAI
Section Editor
N Franklin Adkinson, Jr, MD
Deputy Editor
Anna M Feldweg, MD


Sulfonamide-containing antibiotics are the second most frequent cause of allergic drug reactions, after the beta-lactams (penicillins and cephalosporins). In one large study, the incidence of reactions to trimethoprim-sulfamethoxazole (TMP-SMX) was 34 per 1000 patients exposed, compared with 51 per 1000 for amoxicillin [1]. However, the adverse reactions caused by sulfonamides differ significantly from those attributed to beta-lactams, and the evaluation and management of sulfonamide reactions are distinct. The pathophysiology of allergic (or hypersensitivity) reactions to sulfonamides is complex and poorly understood.

This topic review describes the most prevalent types of reactions to sulfonamides, the evaluation of patients with reported allergy, and cross-reactivity issues. Management options for patients with past reactions who require similar medications again are also presented. Most of the available literature concerns allergic reactions to antimicrobial sulfonamides, particularly TMP-SMX. However, reactions to nonantimicrobial sulfonamides (eg, diuretics, sulfonylureas, and others) and sulfones (eg, dapsone) will be briefly addressed as well.

This review does not address the treatment of acute drug reactions. These are presented elsewhere, according to specific type of reaction. (See "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis" and "Drug eruptions" and "Anaphylaxis: Emergency treatment" and "Drug fever".)


The imprecise term "sulfa drugs" is most often applied to sulfonamide antimicrobials, although it is variably used for other medications as well. This term has contributed to ongoing confusion about relevant cross-reactivity among sulfonamide drugs. It is preferable to avoid "sulfa allergy" and instead document the specific medication that caused the adverse reaction and the symptoms that were involved.

Types of sulfonamides — Sulfonamide medications are drugs that contain a sulfonamide moiety (SO2NH2) [2]. There are two distinct groups of sulfonamides that differ in chemical structure as well as clinical use:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 23, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.
  2. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.
  3. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004; 24:856.
  4. Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm 2013; 70:1483.
  5. Lehmann DF. The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs. Drug Metab Lett 2012; 6:129.
  6. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4:426.
  7. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7:324.
  8. Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006; 40:1594.
  9. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15:9.
  10. Hemstreet BA, Page RL 2nd. Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy 2006; 26:551.
  11. Domínguez-Ortega J, Martínez-Alonso JC, Domínguez-Ortega C, et al. Anaphylaxis to oral furosemide. Allergol Immunopathol (Madr) 2003; 31:345.
  12. Muñoz-Bellido FJ, Terrón M, León A. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 2003; 58:1072.
  13. Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 1988; 25:1347.
  14. Chichmanian RM, Papasseudi G, Hieronimus S, et al. [Hypersensitivity to hypoglycemic sulfonylurea compounds. Are there cross-reactions?]. Therapie 1991; 46:163.
  15. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.
  16. de Frutos C, de Barrio M, Tornero P, et al. Erythema multiforme from sulfaguanidine. Contact Dermatitis 2002; 46:186.
  17. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25:965.
  18. Heckbert SR, Stryker WS, Coltin KL, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132:336.
  19. Nettis E, Calogiuri G, Colanardi MC, et al. Drug-induced aseptic meningitis. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:143.
  20. Bruner KE, Coop CA, White KM. Trimethoprim-sulfamethoxazole-induced aseptic meningitis-not just another sulfa allergy. Ann Allergy Asthma Immunol 2014; 113:520.
  21. Montanaro A. Sulfonamide allergy. Immunol Allergy Clin North Am 1998; 18:843.
  22. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100:136.
  23. Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628.
  24. Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.
  25. Asero R. Detection of patients with multiple drug allergy syndrome by elective tolerance tests. Ann Allergy Asthma Immunol 1998; 80:185.
  26. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.
  27. Lee AG, Anderson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol 2004; 138:114.
  28. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother 2005; 39:290.
  29. Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol 2010; 153:152.
  30. Shapiro LE, Knowles SR, Weber E, et al. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003; 26:187.
  31. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21:2065.
  32. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005; 28:917.
  33. Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol 2005; 32:883.
  34. Sener O, Doganci L, Safali M, et al. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16:268.
  35. Kosseifi SG, Guha B, Nassour DN, et al. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006; 1:9.
  36. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012; 92:194.
  37. Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. JAMA 1991; 265:120.
  38. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991; 88:784.
  39. Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987; 79:442.
  40. Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 2000; 33:517.
  41. Neuman MG, Malkiewicz IM, Phillips EJ, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 2002; 24:728.
  42. Rich JD, Sullivan T, Greineder D, Kazanjian PH. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997; 79:409.
  43. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989; 110:286.
  44. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7:65.
  45. Bonfanti P, Pusterla L, Parazzini F, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Biomed Pharmacother 2000; 54:45.
  46. Hattori N, Hino H. Generalized erythematous skin eruptions due to trimethoprim itself and co-trimoxazole. J Dermatol 1998; 25:269.
  47. Ozkaya-Bayazit E, Güngör H. Trimethoprim-induced fixed drug eruption: positive topical provocation on previously involved and uninvolved skin. Contact Dermatitis 1998; 39:87.
  48. Ozkaya-Bayazit E, Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997; 137:1028.
  49. Moreno Escobosa MC, Cruz Granados S, Moya Quesada MC, Amat López J. Enanthema and fixed drug eruption caused by trimethoprim. J Investig Allergol Clin Immunol 2009; 19:249.
  50. Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy 1999; 54 Suppl 58:28.
  51. Celik G, Pichler WJ, Adkinson NF. Drug allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.1205.
  52. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.
  53. Ditto AM. Drug allergy. In: Patterson's allergic diseases, 6th ed, Grammer LC, Greenberger PA. (Eds).
  54. Earl G, Davenport J, Narula J. Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics. Ann Intern Med 2003; 138:358.
  55. Wall GC, Bigner D, Craig S. Ethacrynic acid and the sulfa-sensitive patient. Arch Intern Med 2003; 163:116.
  56. Juang P, Page RL 2nd, Zolty R. A successful rapid desensitization protocol in a loop diuretic allergic patient. J Card Fail 2005; 11:481.
  57. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987; 93:1255.
  58. Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to sulfasalazine. Am J Med 1982; 73:520.
  59. Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med 1984; 100:512.
  60. Kümmerle-Deschner J, Dannecker G. Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Acta Paediatr 1995; 84:952.
  61. Bax DE, Amos RS. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis 1986; 45:139.
  62. Caumes E, Guermonprez G, Lecomte C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133:465.
  63. Moreno JN, Poblete RB, Maggio C, et al. Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol 1995; 74:140.
  64. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.
Topic Outline